Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Mar 2017
Randomized Controlled Trial Comparative StudyEfficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating moderate to severe psoriasis in a phase II trial. ⋯ Guselkumab demonstrated superior efficacy compared with adalimumab and was well tolerated in patients with psoriasis through 1 year.
-
J. Am. Acad. Dermatol. · Nov 2016
Randomized Controlled Trial Comparative StudyHair follicle-containing punch grafts accelerate chronic ulcer healing: A randomized controlled trial.
A prominent role of hair follicle-derived cells in epidermal wound closure is now well established but clinical translation of basic research findings is scarce. Although skin punch grafts have been used as a therapeutic intervention to improve healing of chronic leg ulcers, they are normally harvested from nonhairy areas, thus not taking advantage of the reported role of the hair follicle as a wound-healing promoter. ⋯ Autologous transplantation of terminal hair follicles by scalp punch grafts induces better healing than punch grafts harvested from nonhairy areas. Hair punch grafting is a minimally invasive surgical procedure that appears to be effective as a therapeutic tool for chronic venous leg ulcers.
-
J. Am. Acad. Dermatol. · Oct 2016
Comparative Study Observational StudyTrends in the diagnosis and clinical features of melanoma in situ (MIS) in US men and women: A prospective, observational study.
The incidence of melanoma in situ (MIS) is increasing, but little is known about its clinical and epidemiologic features. ⋯ We found epidemiologic and clinical differences for in situ and invasive melanomas, which support further examination into the variations in etiologic pathways. The lack of improvement in mortality despite the increase in detection of in situ relative to invasive lesions further highlights the need to improve invasive melanoma-specific clinical screening features.